Biosimilar Approvals: U.S. vs. Europe Insights for Pharma BD

Biosimilar Approvals: U.S. vs. Europe Insights for Pharma BD

Explore the diverging landscapes of biosimilar approvals in the U.S. and Europe. This analysis offers critical insights for pharmaceutical business development teams, investors, and analysts navigating market entry strategies, especially as the FDA moves to slash development costs and the EMA’s longer track record continues to shape global competition.

Key Takeaways

• The FDA’s 2024 draft guidance on streamlining clinical pharmacokinetic (PK) testing could shave up to $20 million off a biosimilar program, a potential 50% savings that may shift the U.S. cost equation for developers.
• Europe’s EMA has recommended 168 biosimilars across eight product classes, far outstripping the FDA’s 50 approved products, reflecting a decade-long head start and a more expansive definition of product variation.
• For BD teams and investors, the strategic choice between U.S. and European market entry now hinges on converging approval timelines but diverging cost structures and competitive crowding — requiring dedicated regulatory intelligence for each region.

How do U.S. and European regulatory pathways compare?

The U.S. Food and Drug Administration and the European Medicines Agency both hold biosimilars to the same standards of pharmaceutical quality, safety, and efficacy that apply to all biological medicines, the EMA states clearly. Yet the two regulators have taken markedly different roads to reach that endpoint.

In 2024, the FDA issued draft guidance recommending that biosimilar developers can skip unnecessary clinical PK testing when scientific justification exists. According to the agency’s press release, this change “could save biosimilar developers up to 50% of their PK study costs, or approximately $20 million, and help lower drug costs.” The guidance signals a clear push to accelerate competition for expensive biologics by trimming clinical burden.

Across the Atlantic, the EMA has been approving biosimilars since 2006, giving it a richer history and a much larger portfolio. A detailed analysis by the law firm Rothwell, Figg, Ernst & Manbeck, updated January 22, 2026 on JD Supra, reports that the FDA has approved 50 biosimilars while the EMA has approved 70. However, the EMA’s broader count of biosimilar recommendations totals 168 across product classes including human growth hormone, granulocyte colony-stimulating factor, erythropoiesis stimulating agents, insulins, and TNF inhibitors — more than triple the FDA’s number. The gap stems from the EMA’s head start and from differences in how each regulator counts product extensions.

Both agencies still require a stepwise comparability exercise to prove a biosimilar is highly similar to a reference product. But the FDA’s new PK guidance could narrow the time-to-market gap by reducing the need for redundant clinical trials, a shift the EMA might watch closely.

What do these differences mean for pharma business development and regulatory teams?

The diverging regulatory speeds and cost structures create distinct strategic landscapes for biosimilar developers. For BD teams and investors, the choice of market entry pathway directly affects pipeline prioritization, partnership opportunities, and competitive positioning.

Companies targeting Europe benefit from the EMA’s established track record and a larger base of approved biosimilars, which often yields more predictable regulatory timelines. The EMA’s extensive experience across multiple classes means regulators there have seen more comparability exercises, potentially smoothing the path for new applicants. But the market is also more crowded — roughly 70 approved biosimilars already jostle with reference biologics in many therapeutic areas, squeezing margins and forcing earlier price pressure.

In the U.S., the FDA’s PK guidance could significantly lower clinical costs. Saving $20 million per program is meaningful for any sponsor, especially smaller developers. That cost advantage, combined with a less saturated market with only 50 approved biosimilars as of early 2026, makes the U.S. attractive for first movers willing to navigate a younger regulatory pathway. The FDA’s process has historically been slower than the EMA’s, but the gap is shrinking as the agency builds experience and introduces efficiencies like the new guidance.

For regulatory teams, the takeaway is clear: maintain separate intelligence functions for each region. A program that qualifies for streamlined PK testing in the U.S. may still require full clinical trials in Europe, and vice versa. Companies that adapt their clinical plans to exploit the most favorable pathway — perhaps launching first in the U.S. to capture cost savings, then expanding to Europe — will be best positioned to maximize returns.

Investors should also monitor competitive dynamics. As the FDA’s guidance is finalized, the U.S. pipeline could accelerate, eroding the pricing power of reference biologics faster than anticipated. Meanwhile, the EMA’s broader approval base means European markets already feel pricing pressure but also see more strong competition from multiple biosimilars. A 2021 overview in PMC noted that the biosimilar landscape remains highly dynamic, with regulatory changes on both sides of the Atlantic shaping investment decisions in real time.

Frequently Asked Questions

Related coverage

• Maersk Europe Market Update June 2026: Key Changes for Pharma Supply Chains
• Regulatory round-up: 2 February 2026 – EMA opinions, FDA approvals, and what they mean for pharma
• India-Oman CEPA Fast-Tracks Drug Approvals, Cuts Export Barriers for Pharma